| |
Mean ± SD (n = 15)
|
Min – max (n = 15)
|
|---|
|
Gender (n male/women)
|
12/3
| |
|
Age (yr)
|
67 ± 7
|
58–78
|
|
Weight (kg)
|
81 ± 15
|
51–109
|
|
Height (cm)
|
176 ± 9
|
158–188
|
|
BMI
|
26 ± 4
|
19–37
|
|
BSA
|
2.0 ± 0.2
|
1.5–2.3
|
|
NYHA classification n (%)
| | |
|
Class II
|
7 (47)
| |
|
Class III
|
5 (33)
| |
|
Class IV
|
3 (20)
| |
|
Echocardiography
| | |
|
LVEF (%)
|
31 ± 11
|
17–53
|
|
RV dysfunction
| | |
|
TAPSE < 16 mm (n)
|
4/15
| |
|
Pulmonary hypertension
| | |
|
TR velocity > 2.8 m/s (n)
|
2/15
| |
|
Electrocardiogram
| | |
|
Heart rate
|
72 ± 17
|
50–110
|
|
QRS duration (ms)
|
151 ± 27
|
118–194
|
|
IVMD (ms) in 13 patients
|
42 ± 14
|
20–60
|
|
SPWMD (ms) in 11 patients
|
152 ± 70
|
10–240
|
|
Comorbidities n (%)
| | |
|
Hypertension
|
5 (33)
| |
|
Coronary artery disease
|
11 (73)
| |
|
Congestive heart failure
|
14 (93)
| |
|
COPD
|
6 (40)
| |
|
Diabetes mellitus
|
3 (20)
| |
|
Medication n (%)
| | |
|
Beta-blocker
|
12 (80)
| |
|
ACE inhibitors
|
11 (73)
| |
|
AT II blockers
|
2 (13)
| |
|
Loop diuretics
|
12 (80)
| |
|
K-sparing agents
|
6 (40)
| |
|
Statins
|
14 (93)
| |
|
Laboratory
| | |
|
Creatinine (μmol/L)
|
105 ± 28
|
31–160
|
|
NT-proBNP (pmol/L)
|
162 ± 111
|
36–440
|
-
SD standard deviation, BMI body mass index, BSA body surface area, NYHA New York Heart Association, LVEF left ventricular ejection fraction, RV right ventricle, TAPSE tricuspid annular plane systolic excursion, TR tricuspid regurgitation, IVMD interventricular mechanical delay, SPWMD septal to posterior wall motion delay, COPD chronic obstructive pulmonary disease, ACE angiotensin-converting enzyme, AT II angiotensine-II-receptor antagonist, K-sparing potassium sparing, NT-proBNP N-terminal pro-B-type natriuretic peptide
